Read by QxMD icon Read

Clinical Breast Cancer

Ning Liu, Kimberly J Johnson, Cynthia X Ma
BACKGROUND: Male breast cancer is rare and understudied compared with female breast cancer. A current comparison with female breast cancer could assist in bridging this gap. Although conflicting data have been reported on male and female survival outcomes, data from 1973 through 2005 in the Surveillance, Epidemiology, and End Results (SEER) program have demonstrated that the improvement in breast cancer survival in men has fallen behind that of women. As treatment for breast cancer has improved significantly, an updated analysis using a contemporary population is necessary...
June 27, 2018: Clinical Breast Cancer
Leyla Nasehi, Charles D Sturgis, Nidhi Sharma, Paulette Turk, Benjamin C Calhoun
BACKGROUND: The long-term risk for patients with benign intraductal papillomas (IDPs) on core needle biopsy (CNB) who are not upgraded on excision is not well-defined. The goal of this study was to determine the cumulative breast cancer (BC) incidence for patients with benign IDP on CNB. MATERIALS AND METHODS: There were 152 benign IDPs diagnosed on CNB between 2003 and 2008. Radiology and pathology data were reviewed by breast radiologists and pathologists. Clinical follow-up was obtained from the electronic medical record (Epic)...
June 21, 2018: Clinical Breast Cancer
Radhika Bali, Hadyn K N Kankam, Nikhilesh Borkar, Elena Provenzano, Amit Agrawal
INTRODUCTION: Oncoplastic breast surgery (OBS) can be applied in larger tumors or in patients with high tumor-to-breast ratio without compromising oncologic safety. Inherent larger excisions may increase the probability of clear margins. We compare postoperative outcomes between simple wide local excision (WLE) and OBS assuming 3 different margin distances. PATIENTS AND METHODS: Single oncoplastic surgeon data between April 2014 and September 2016, including tumor and treatment details, for WLE or OBS were reviewed...
June 19, 2018: Clinical Breast Cancer
Philip Hepp, Peter A Fasching, Matthias W Beckmann, Tanja Fehm, Jessica Salmen, Carsten Hagenbeck, Bernadette Jäger, Peter Widschwendter, Nikolaus de Gregorio, Fabienne Schochter, Sven Mahner, Nadia Harbeck, Tobias Weissenbacher, Ayse-Gül Kurt, Thomas W P Friedl, Wolfgang Janni, Brigitte Rack
BACKGROUND: Little is known about the effect of granulocyte colony-stimulating factor (G-CSF) treatment during adjuvant chemotherapy on prognostic markers. The present study explored the association between G-CSF and changes in cancer antigen (CA)27.29 and circulating tumor cell (CTC) levels during therapy. PATIENTS AND METHODS: A total of 3754 node-positive or high-risk node-negative early-stage breast cancer patients were treated within the SUCCESS-A trial (simultaneous study of gemcitabine-docetaxel combination adjuvant treatment, as well as extended bisphosphonate and surveillance-trial)...
June 18, 2018: Clinical Breast Cancer
Victor Sarradin, Florence Dalenc, Vincent Sibaud, Emilie Tournier, Henri Roché
No abstract text is available yet for this article.
June 18, 2018: Clinical Breast Cancer
Xiao Zhu, Jun-Ming Huang, Kun Zhang, Long-Jie Xia, Lan Feng, Ping Yang, Meng-Ya Zhang, Wei Xiao, Hui-Xia Lin, Ying-Hua Yu
BACKGROUND: Contrast-enhanced spectral mammography (CESM) is a new image examination technology that has developed over the past few years. As CESM technology keeps improving, a current meta-analysis review is needed to systematically evaluate the potential diagnostic value of CESM. METHODS: A total of 18 studies were included in the review. Sensitivity, specificity, and other important parameters of CESM accuracy for breast cancer diagnosis were pooled and analyzed using random-effects models...
June 15, 2018: Clinical Breast Cancer
Jonathan Chen, Xian Wu, Paul Christos, Weisi Yan, Akkamma Ravi
INTRODUCTION: Breast cancer patients with tumors > 5 cm but without nodal disease who undergo mastectomy present a clinical challenge regarding the appropriate adjuvant treatment. Traditionally, postmastectomy radiation therapy (PMRT) was the standard of care. However, recent studies have suggested local failure rates without PMRT might be low enough to omit RT. This might be especially true in the elderly. PATIENTS AND METHODS: Women aged ≥ 75 years with a diagnosis of T3N0 breast cancer who had undergone mastectomy were identified from the Surveillance, Epidemiology, and End Results (SEER) 18 database...
June 15, 2018: Clinical Breast Cancer
Leah Drost, Caitlin Yee, Henry Lam, Liying Zhang, Matt Wronski, Claire McCann, Justin Lee, Danny Vesprini, Eric Leung, Edward Chow
Radiotherapy (RT) for breast cancer improves survival, but poses risk to the heart, resulting from a linear relationship between RT dose and heart disease. This review presents studies worldwide reporting heart doses from whole breast RT after 2014 to update a previous systematic review (Taylor et al, Int J Radiat Oncol Biol Phys, 2015) in order to determine patterns of current heart dosimetry among varying RT regimens. Studies published between January 2014 and September 2017 were included if they reported whole heart dose based on whole breast RT technique or treatment position and had a sample size of ≥ 20 patients...
June 14, 2018: Clinical Breast Cancer
Matthew Green, Foteini Neamonitou, Raghavan Vidya
Involvement of axillary lymph nodes is an important prognostic factor in relationship to the management of breast cancer. However, the use of neoadjuvant systemic therapy is widespread in the treatment of positive axilla and such treatment leads to downstaging of axillary disease. Hence, the role of targeted axillary lymph node biopsy appears to play a vital role after primary systemic therapy. Given that this is a relatively novel approach, we have discussed the evidence for this approach and the different techniques currently available for localization of biopsy-proven metastatic axillary lymph nodes...
June 8, 2018: Clinical Breast Cancer
Yunju Kim, Sung Hoon Sim, Boram Park, Keun Seok Lee, In Hye Chae, In Hae Park, Youngmi Kwon, So-Youn Jung, Seeyoun Lee, Kyounglan Ko, Han-Sung Kang, Chan Wha Lee, Eun Sook Lee
PURPOSE: To investigate the diagnostic performance of magnetic resonance imaging (MRI) for predicting pathologic complete response after neoadjuvant chemotherapy (NAC) depending on subtypes of breast cancer using different interpretation thresholds of MRI negativity. PATIENTS AND METHODS: A total of 353 women with breast cancer who had undergone NAC were included. Pathologic examination after complete surgical excision was the reference standard. Tumors were divided into 4 subtypes on the basis of expression of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2)...
June 7, 2018: Clinical Breast Cancer
Hitomi Mori, Makoto Kubo, Masaya Kai, Vittoria Vanessa Velasquez, Kanako Kurata, Mai Yamada, Masayuki Okido, Syoji Kuroki, Yoshinao Oda, Masafumi Nakamura
BACKGROUND: The inexpensive prediction of the characteristics of BRCA-mutated breast cancer as "BRCAness" using the somatic cells of patients with breast cancer could be useful for developing a therapeutic strategy. Our objective was to correlate BRCAness with the clinicopathologic features, including a family history (FH) of cancer, in breast cancer patients with a high risk of BRCA mutations. PATIENTS AND METHODS: The present study included 124 patients, including 55 with early-onset and 77 with triple-negative breast cancer, who had undergone resection at Kyushu University Hospital from 2005 to 2014...
June 2, 2018: Clinical Breast Cancer
Charalampos Siotos, Michael McColl, Kevin Psoter, Richard C Gilmore, Mohamad E Sebai, Kristen P Broderick, Lisa K Jacobs, Stephanie Irwin, Gedge D Rosson, Mehran Habibi
INTRODUCTION: Various factors affect breast cancer prognosis; however, little information is available regarding the role of primary tumor site. The purpose of this study was to compare the survival and clinicopathologic characteristics of patients with breast cancer by primary tumor location. MATERIALS AND METHODS: We analyzed a prospectively collected single-institution breast cancer registry. Univariate and multivariable analyses were used to evaluate the association of tumor site with positive lymph node status, presence of metastasis, time to recurrence or death, and events of recurrence or death...
May 29, 2018: Clinical Breast Cancer
Hye Jin Kim, Eunyoung Kang, Jee Hyun Kim, Se Hyun Kim, Yu Jung Kim, In Ah Kim, Keun-Yong Eom, Su Min Chae, Kyu Min Kang, Eun Kyu Kim, Sung-Won Kim
BACKGROUND: Several studies have suggested that primary tumor removal improved overall survival for patients with stage IV breast cancer. However, the survival benefit of local treatment remains controversial. The purpose of the present study was to determine whether surgical removal of the primary tumor provides survival benefits to patients with stage IV breast cancer. PATIENTS AND METHODS: We retrospectively reviewed the medical records of 155 patients with an initial diagnosis of stage IV breast cancer at Seoul National University Bundang Hospital from 2003 to 2014...
May 28, 2018: Clinical Breast Cancer
Meixuan Chen, Barbara Pockaj, Mariacarla Andreozzi, Michael T Barrett, Sri Krishna, Seron Eaton, Ruifang Niu, Karen S Anderson
BACKGROUND: Activation of the JAK/STAT pathway is common in triple-negative breast cancer (TNBC) and affects the expression of genes controlling immune signaling. A subset of TNBC cases will have somatic amplification of chromosome 9p24.1, encoding PD-L1, PD-L2, and JAK2, which has been associated with decreased survival. MATERIALS AND METHODS: Eleven TNBC cell lines were evaluated using array comparative genomic hybridization. A copy number gain was defined as an array comparative genomic hybridization log2 ratio of ≥ 1...
May 26, 2018: Clinical Breast Cancer
Anne-France Leclerc, Justine Slomian, Guy Jerusalem, Philippe Coucke, Thierry Bury, Dorian Deflandre, Martine Devos, Olivier Bruyère, Marguerite Foidart-Dessalle, Jean-François Kaux, Jean-Michel Crielaard, Didier Maquet
BACKGROUND: Various clinical trials have demonstrated the benefits of physical training offered during and/or after breast cancer treatments. However, given the variety of adverse events that may be encountered, physical training could be combined with psychologic, relational, and social guidance. This kind of multidisciplinary program, as well as its long-term effects, have been little studied so far. Therefore, the objective of our study was to determine the benefits at 3, 6, 12, and 24 months of a 3-month exercise and education program among women after breast cancer treatment...
May 19, 2018: Clinical Breast Cancer
Michael Co, Judy Ng, Ava Kwong
Air travel has long been a dilemma in post-breast cancer surgery patients. Anecdotal reports have described adverse outcomes on surgical wound, implants, and lymphedema during air travel. This review aims to evaluate the best evidence from the literature concerning the air travel safety in breast cancer patients. A comprehensive review was performed of the Medline, Embase, CINAHL, and Cochrane databases using a predefined strategy. Retrieved studies were independently screened and rated for relevance. Data were extracted by 2 researchers...
May 17, 2018: Clinical Breast Cancer
Caitlin Yee, Leah Drost, Mark Niglas, Edward Chow, Danny Vesprini
No abstract text is available yet for this article.
May 9, 2018: Clinical Breast Cancer
Hong-Fei Gao, Ci-Qiu Yang, Min-Yi Cheng, Teng Zhu, Mei Yang, Liu-Lu Zhang, Kun Wang
INTRODUCTION: The prognostic value of the mesenchymal-epithelial transition (MET) in triple-negative breast cancers (TNBCs) remains controversial. A meta-analysis of the impact of MET in TNBCs was performed by searching published data. METHODS: PubMed and Embase databases were searched for eligible literature. The principal outcome measures were hazard ratios (HRs) for recurrence-free survival or overall survival according to MET expression. Combined HRs were calculated using fixed- or random-effects models according to heterogeneity...
May 7, 2018: Clinical Breast Cancer
Patrick J McIntire, Lina Irshaid, Yifang Liu, Zhengming Chen, Faith Menken, Eugene Nowak, Sandra J Shin, Paula S Ginter
BACKGROUND: CD8+ tumor-infiltrating lymphocytes (TILs) have emerged as a prognostic indicator in triple-negative breast cancer (TNBC). There is debate surrounding the prognostic value of hot spots for CD8+ TIL enumeration. METHODS: We compared hot spot versus whole-tumor CD8+ TIL enumeration in prognosticating TNBC using immunohistochemistry on whole tissue sections and quantification by digital image analysis (Halo imaging analysis software; Indica Labs, Corrales, NM)...
May 7, 2018: Clinical Breast Cancer
Margaret M Kozak, Clare E Jacobson, Rie von Eyben, Emily Walck, Erqi L Pollom, Melinda Telli, Kathleen C Horst
PURPOSE: To identify patterns of distant failure (DF) in premenopausal women receiving neoadjuvant chemotherapy (NAC) for breast cancer. PATIENTS AND METHODS: Premenopausal patients treated with NAC between 2005 and 2015 at a single institution were retrospectively reviewed. Timing and location of local, regional, and distant metastases were described. Predictors for DF and overall survival (OS) were analyzed. RESULTS: Of 225 patients, there were 24 (10...
May 7, 2018: Clinical Breast Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"